Cisplatin
- PDF / 158,364 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 69 Downloads / 161 Views
1
S
Cisplatin Ototoxicity in children: 11 case reports
In a retrospective study, 11 children were identified after developing ototoxicity during cisplatin-based chemotherapy for medulloblastoma [see table]. Following diagnosis of medulloblastoma, patients received maximal safe resection, craniospinal irradiation and intensitymodulated radiation therapy to the posterior fossa and/or tumour bed, followed by cisplatin-based chemotherapy [routes not stated] according to SJMB96 or Children’s Oncology Group A9961 protocols. Three patients subsequently developed grade 4 ototoxicity, while the remaining patients developed grade 3 ototoxicity. Hearing loss was unilateral in six patients and bilateral in five. The cisplatin dosage was reduced by 50%, and nine patients required hearing aids or an FM-assisted listening device [patient outcomes not clearly stated].
Patient characteristics Patient/ sex/age (y) 1/M/9.8 2/M/7.6 3/F/12a 4/F/3 5/M/4.2 6/M/9 7/M/6.8a 8/M/10a 9/M/6.5a 10/M/5a 11/M/4.3
Cisplatin dose (mg/m2)b
Onset from RT (m)
Outcome
450 300 225 525 300 300 300 262.5 300 225 300
12 10 3 7 53 66 57 47 4 5 17
hearing aid hearing aid hearing aids not stated hearing aid not stated FM device hearing aids FM device hearing aids hearing aid
a patients with bilateral hearing loss; b frequencies not stated; RT radiotherapy.
Paulino AC, et al. Ototoxicity after intensity-modulated radiation therapy and cisplatin-based chemotherapy in children with medulloblastoma. International Journal of Radiation Oncology, Biology, Physics 78: 1445-1450, No. 5, Dec 2010. Available from: URL: http://dx.doi.org/10.1016/j.ijrobp.2009.09.031 803046821 USA
»
Editorial comment: An additional 22 patients developed grade 0–2 ototoxicity during cisplatin-based chemotherapy, but individual patient identifiers were not provided by the authors.
0114-9954/10/1333-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Reactions 8 Jan 2011 No. 1333
Data Loading...
